Gene therapy for male erectile dysfunction.
The potential clinical advantages of a gene transfer therapy-based approach to treatment of genitourinary smooth muscle-based disorders are several: potential single therapy for restoration of normal bladder or erectile function; eliminating the need for daily medication; use in combination with other therapies to reduce dose requirements and side effects; and development of mechanism-based, patient-specific treatment approaches. With the safe administration of hMax-K to men with erectile dysfunction in the first human phase 1 trial and the initiation of the phase 1 trial of hMaxi-K for patients who have detrusor overactivity, we have entered an exciting new era in the development of safe enduring therapies for genitourinary disorders.
Melman
Arnold
A
Department of Urology, Albert Einstein College of Medicine, Bronx, NY, USA. ameman@aecom.yu.edu
D000818:Animals; D007172:Erectile Dysfunction / Q000628:therapy*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D007473:Ion Channels / Q000502:physiology*; D008297:Male; D009130:Muscle, Smooth / Q000502:physiology*; D016896:Treatment Outcome
D007473:Ion Channels